You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: NIAMSDESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility
SBC: NOVALEX THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
SBC: DXDISCOVERY INC Topic: NIAIDDESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors
SBC: NOVALEX THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nrf2 activator for the treatment of scleroderma
SBC: CUREVEDA, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis
SBC: Exicure, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells
SBC: IMMUVEN, INC. Topic: NCIProject Summary The goal of this STTR grant application is to engineer powerful NK cell-based cytolytic effector cells for therapeutic applications. The cells will combine the selectivity and specificity of T cells and the ability of NK cells to mediate effective cytolytic activity against a wide spectrum of aberrant cells, including those with impaired adhesion properties. To achieve this goal we ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health